ArticleFrontiers in immunology2025
Quantitative nodal burden as a predictive marker for chemotherapy benefit in postoperative ampullary adenocarcinoma: a multi-institution population-based study.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The effectiveness of adjuvant chemotherapy (ACT) in ampullary adenocarcinoma (AA) patients and under what conditions ACT should be applied are not clearly defined. Methods: The study encompassed a series of consecutive AA patients who underwent curative surgical resection. These patients were sourced from the National Cancer Center of China, spanning the years 1998 to 2020, as well as from 12 registries within the Western surveillance, epidemiology, and end results program, covering the period from 2004 to 2017. The quantitative nodal burden was evaluated using the log odds of positive lymph nodes (LODDS). The correlation between ACT and overall survival (OS), recurrence-free survival (RFS), and cancer-specific survival (CSS), was meticulously evaluated using Cox proportional hazards regression models and tested by interaction analysis. Results: Despite its rarity, a total of 948 and 225 eligible patients were included in the Western cohort and the China cohort, respectively. ACT was not significantly associated with improved long-term survival of unselected AA patients in both the China cohort (OS: Conclusion: This study emphasizes the potential of LODDS to inform personalized therapeutic decisions in the management of AA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.